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Abstract The treatment of patients with diffuse large B cell
lymphoma (DLBCL) would be greatly facilitated with a rapid
method for determining prognosis that can be performed more
easily and earlier than cytological or specific pathological
examinations. It has been suggested that newly diagnosed
patients with DLBCL who have low maximum standard
uptake value (SUVmax) on
18F-fluorodeoxyglucose positron
emission tomography (FDG-PET) are more likely to be suc-
cessfully treated and remain in remission compared with
patients with high SUVmax, but this concept has been poorly
studied. We retrospectively analyzed 50 patients with de novo
DLBCL to evaluate the relationship between the SUVmax and
disease progression. For patients with low SUVmax (n010)
and high SUVmax (n040) (P00.255), respectively, the 3-year
overall survival rates were 90 and 72 %, and the progression-
free survival (PFS) rates were 90 and 39 % (P00.012). By
multivariate analysis, the revised International Prognostics
Index (R-IPI) and SUVmax at diagnosis were shown to predict
longer PFS. The 3-year PFS for patients with low SUVmax
classified into the good prognosis group by R-IPI was 100 vs.
62 % for those with high SUVmax (P00.161), and patients
with low SUVmax classified into the poor prognosis group by
R-IPI was 80 vs. 18% for those with high SUVmax (P00.050).
We conclude that the SUVmax on FDG-PET for newly diag-
nosed patients with DLBCL is an important predictor of
disease progression, especially for patients with poor progno-
sis by R-IPI.
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Introduction
Diffuse large B cell lymphoma (DLBCL) is the most common
aggressive form of non-Hodgkin’s lymphoma. Combination
chemotherapy with rituximab is initially administered to most
newly diagnosed patients with DLBCL [1–4]. However, if the
patients relapse after the initial chemotherapy, their lymphoma
can be poorly managed because most DLBCL cases ultimately
become chemotherapy-resistant unless treated with high-dose
chemotherapy with autologous stem cell transplantation
(ASCT) [5, 6]. Instead of combination chemotherapy with
rituximab, other treatments including more intensive chemo-
therapy, up-front ASCTafter the first remission, or other newly
developed drugs are required to improve survival of the patients
who are at high risk of relapse [7, 8]. Therefore, defining
prognostic factors that can easily and accurately classify
patients with untreated DLBCL into appropriate risk groups
for relapse is highly important for disease management.
Although 18F-fluorodeoxyglucose positron emission to-
mography (FDG-PET) imaging for DLBCL have been widely
utilized to evaluate the staging and residual lesions after treat-
ment with high sensitivity [9–12], the relevance of the maxi-
mum standard uptake value (SUVmax) in this technique to
disease outcome has been poorly studied. The SUVmax at the
Y. Miyazaki (*) :M. Yasukawa
Department of Bioregulatory Medicine,
Ehime University Graduate School of Medicine,
Shitsukawa,
Toon, Ehime 791-0295, Japan
e-mail: miya2ymy@yahoo.co.jp
Y. Miyazaki :Y. Nawa : S. Kohashi :K. Nakase :M. Hara
Division of Hematology, Ehime Prefectural Central Hospital,
Matsuyama, Ehime, Japan
M. Miyagawa
Division of Radiology, Ehime Prefectural Central Hospital,
Matsuyama, Ehime, Japan
Ann Hematol (2013) 92:239–244
DOI 10.1007/s00277-012-1602-3
biopsy site of non-Hodgkin’s lymphoma patients has been
reported to correlate with the proliferation potential [13]. An-
ecdotal cases from our hospital (unpublished) also suggest that
patients with low SUVmax DLBCL before treatment are more
likely to remain in remission, while those with high SUVmax
DLBCL are more likely to relapse. However, this idea has not
been confirmed by a systematic analysis of clinical cases.
Therefore, in this study, we retrospectively analyzed 50 patients
with DLBCL in order to examine the relationship between the
initial SUVmax of FDG-PET and disease progression.
Patients and methods
Eligibility criteria
In this study, patients with de novo DLBCL, excluding those
with transformation from indolent lymphoma, diagnosed be-
tween April 2006 and December 2009 at Ehime Prefectural
Central Hospital (Matsuyama, Japan) were retrospectively
analyzed. FDG-PET imaging was performed in all patients
before the treatment, and the SUVmax at the primary lesion
was measured. The patients subsequently received combina-
tion chemotherapy with rituximab. Patients whose primary
lesions were excised surgically before FDG-PET imaging or
who were treated palliatively, including only radiotherapy or
only rituximab, were excluded from this study. The observa-
tion period was from April 2006 to March 2011.
PET/CT acquisition and processing
FDG-PET/CT imaging was performed using a multi-slice
PET/CT camera (Discovery STE with 16-slice CT; GE
Healthcare). All patients had fasted for a minimum of 6 h, with
a blood glucose level of 80–120 mg/dL before intravenous
administration of 18F-FDG. Awhole-body image was obtained
exactly 60 min after the intravenous administration of 222–
370 MBq (6–10 mCi) of 18F-FDG. The PET emission images
were corrected for measured attenuation and reconstructed
using an ordered-subset expectation maximization iterative
algorithm per the manufacturer’s instructions. Integrated PET
and CT images were reviewed on AdvantageWorkstations (GE
Healthcare). Display field of view was 60×60 cm, which
consisted of 192×192 matrixes, on the display. Voxel size
was 3.125×3.125×3.27 mm3. For each PET data set, in
patients with multiple lesions, the tumor with the most intense
FDG uptake among all foci was identified by the maximal
counts. A volumetric region of interest was approximately
8 cm3 (250 voxels) or more and set on the axial fusion images
of PET and CT to calculate SUVmax. A volumetric region of
interest encompassing the entire tumor was drawn to ensure
correct identification of the maximal counts, and the SUVmax
was calculated.
Treatment
All patients received rituximab-containing combination chemo-
therapy as an initial treatment. The cyclophosphamide, doxoru-
bicin, vincristine, and prednisolone with rituximab (R-CHOP)
regimen was administered to younger patients (<70 years old)
with DLBCL, and the pirarubicin, cyclophosphamide, vincris-
tine, and prednisolone with rituximab (R-THPCOP) regimen
was administered to elderly patients (≥70 years old). Most
patients with advanced-stage disease, defined as Ann Arbor
stages III or IV, or stage I and II with bulky disease (≥10 cm),
received six to eight cycles of R-CHOP or R-THPCOP every
21 days. Only the patients who had Ann Arbor stages I and II
without bulky disease received three cycles of R-CHOP or R-
THPCOP and field radiation therapy. Complete remission (CR)
was defined by FDG-PET scan according to the recently pub-
lished criteria [9]. All relapsed patients received salvage che-
motherapy, and ASCTwas performed in eligible cases.
Statistical analysis
Overall survival (OS) was defined as the time from the start of
chemotherapy to death from any cause. Progression-free sur-
vival (PFS) was defined as the time from the start of chemo-
therapy to relapse or death. The Mann–Whitney U test was
used to calculate the differences between two groups. The
probabilities of OS and PFS were estimated by the Kaplan–
Meier method. The association of various factors with the
hazards of failure for the time-to-endpoint PFS was estimated
using the Cox proportional hazard regression model. A P
value of <0.05 was considered statistically significant. SPSS
version 17.0 was used for all analyses.
Results
Patients and characteristics
Fifty patients who met the eligibility criteria were analyzed.
Clinical characteristics including International Prognostic
Index (IPI) factors [14], revised IPI (R-IPI) [15], and the
individual treatments are listed in Table 1. Most patients
(90 %) received six to eight cycles of R-CHOP or R-
THPCOP. Other patients (10 %) received three cycles of
R-CHOP or R-THPCOP and field radiation therapy. No
patients underwent up-front ASCT after R-CHOP or R-
THPCOP. All patients experiencing refractory and relapsed
DLBCL (n026) were treated with salvage chemotherapy,
and seven patients (27 %) who achieved complete or partial
response and were 70 years old or younger underwent
ASCT with high-dose chemotherapy.
The patients were first divided into two prognostic factor
groups at various (10, 15, 20, 25, 30, or 35) in order to
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Table 1 Patients characteristics
SUVmax maximum standardized
uptake value, IPI International
Prognostic Index, PS Eastern
Cooperative Oncology Group
Performance Status, LDH lactate
dehydrogenase, DLBCL diffuse
large B cell lymphoma, NOS not
otherwise specified, THRLBCL
T cell/histiocyte-rich large B cell
lymphoma, PCDLBCL primary
cutaneous diffuse large B cell
lymphoma, PMBL primary me-
diastinal large B cell lymphoma,
sIL-2R soluble interleukin-2 re-
ceptor, LNs lymph nodes, R-
CHOP cyclophosphamide,
doxorubicin, vincristine, and




All (n050) Low SUVmax (n010) High SUVmax (n040) P value
Median SUVmax (range) 21.0 (8.2–47.1) 11.4 (8.2–14.7) 22.1 (15.0–47.1) <0.001
Median age (range) 66 (41–85) 63 (49–82) 67 (41–85) 0.280
Male/female 32/18 4/6 28/12 0.080
IPI factors
Age >60 years 37 8 29 0.632
PS >1 16 1 15 0.099
LDH >normal 32 5 27 0.307
Extranodal site >1 16 4 12 0.548
Stage III/IV 31 6 25 0.885
DLBCL subgroup/subtype
NOS 42 10 32
THRLBCL 2 0 2
PCDLBCL 4 0 4
PMBL 2 0 2
IPI H/I, H 30 5 25 0.475
Revised IPI 0.431
Very good 5 2 3
Good 16 3 13
Poor 29 5 24
Bulky mass 5 0 5 0.243
sIL-2R >normal 39 7 32 0.499
Primary lesion 0.401
LNs 24 6 18
Others 26 4 22
Treatment 0.161
R-CHOP 36 9 27
R-THPCOP 14 1 13
Complete remission 39 9 30 0.311
Recurrence 26 1 25 0.003
Alive/death 38/12 9/1 29/11 0.251
Fig. 1 OS (a) and PFS (b)
based on SUVmax
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determine the appropriate cutoff point, and then OS and PFS
were analyzed. Although OS curves were not significantly
different between each pair of groups for all cutoff values,
PFS curves were significantly higher in patients with the
SUVmax <15 than in those with the SUVmax ≥15. Other
cutoff values for PFS curves were not statistically signifi-
cant. Thus, we determined that the SUVmax cutoff value
should be 15 in this study.
Univariate and multivariate analysis of OS and PFS
for patients with low- and high SUVmax
The median follow-up time was 32.7 months (range, 4.8–
58.3 months). Patients with SUVmax <15 (low SUVmax)
(n010) and those with SUVmax ≥15 (high SUVmax) (n040)
had similar backgrounds regarding age, sex, IPI factors, IPI
classification, R-IPI classification, and individual treatment
(Table 1). The CR rate of all patients was 78 %. CR rates of
patients with low SUVmax and those with high SUVmax were
90 and 75 %, respectively (P00.311). However, patients
with low SUVmax had a significantly lower recurrence rate
than that of those with high SUVmax values (P00.003).
The 3-year OS rates for patients with low SUVmax and for
those with high SUVmax were 90 and 72 %, respectively
(P00.255) (Fig. 1a). The 3-year PFS rate in each group was
90 and 39 %, respectively (P00.012) (Fig. 1b). While no
factors could predict OS, multivariate analysis of PFS
showed that the R-IPI [hazard ratio (HR) 3.37 (1.35–8.39),
P00.009] and low SUVmax [HR 7.49 (1.00–55.95), P0
0.049] were good independent prognostic factors (Table 2).
Table 2 Multivariate analysis of risk factors for OS and PFS
OS PFS
HR (95 % CI) P HR (95 % CI) P
Revised IPI 1.92 (0.58–6.36) 0.287 3.37 (1.35–8.39) 0.009
Low SUVmax 2.51 (0.31–20.03) 0.385 7.49 (1.00–55.95) 0.049
Bulky mass 1.02 (0.21–4.99) 0.979 1.29 (0.37–4.51) 0.693
sIL-2R >normal 2.31 (0.27–19.42) 0.441 0.85 (0.27–2.67) 0.775
Primary lesions except LNs 1.49 (0.42–5.23) 0.533 1.01 (0.44–2.29) 0.988
OS overall survival, PFS progression-free survival, HR hazard ratio, 95 % CI 95 % confidence interval, IPI International Prognostic Index, SUVmax
maximum standardized uptake value, sIL-2R soluble interleukin-2 receptor, LNs lymph nodes
Fig. 2 PFS of all patients divided into “very good,” “good,” and “poor” prognosis groups by R-IPI (a), of patients in the “good” prognosis group
according to SUVmax (b), and of patients in the “poor” prognosis group according to SUVmax (c)
242 Ann Hematol (2013) 92:239–244
Analysis of R-IPI combined with SUVmax
According to the R-IPI categories, all patients in this study
were divided into prognosis groups of “very good” (n05),
“good” (n016), and “poor” (n029), and the 3-year OS and
PFS for each group were 100, 81, and 68 % (P00.167) and
100, 69, and 29 % (P00.016) (Fig. 2a), respectively. In the
very good prognosis group, no patients had a recurrence of
DLBCL. In the good prognosis group, the 3-year OS and
PFS for patients with low SUVmax and those with high
SUVmax were 100 and 77 % (P00.386) and 100 and 62 %
(P00.161), respectively (Fig. 2b). In the poor prognosis
group, the 3-year OS and PFS for patients with low SUVmax
and those with high SUVmax were 80 and 68 % (P00.549)
and 80 and 18 % (P00.050), respectively (Fig. 2c).
Discussion
A relatively higher proportion of patients administered ini-
tial chemotherapy including rituximab have been shown to
be successfully treated and remain in remission from newly
diagnosed DLBCL, compared with those receiving no rit-
uximab [1–4], but a large number of patients still undergo
relapses. Treatment strategies other than R-CHOP are either
initially more intensive chemotherapy or high-dose chemo-
therapy followed by up-front ASCT or newly developed
drug. More useful prognostic factors are clearly required to
identify patients with poorly managed DLBCL. However,
most cytological or pathological prognostic factors for
patients with DLBCL, such as bcl-2, bcl-6, CD5, CD10,
and MUM-1 [16–18], are relatively expensive or time-
consuming to implement for general clinical practice, since
those measurements can be performed only at specific hos-
pitals or external laboratories.
Our results indicate that the SUVmax of FDG-PET in the
primary diagnosis of DLBCL is an important predictor of
progression after the initial treatment, especially for patients
categorized into the poor prognostic group by R-IPI. Further-
more, most patients with low SUVmax or categorized into the
very good prognostic group by R-IPI sustained CR only with
R-CHOP or R-THPCOP therapy. The SUVmax has been
reported to correlate with the MIB-1 labeling index (i.e.,
proliferation potential), a known prognostic factor in DLBCL
patients treated with R-CHOP [13, 19]. Therefore, DLBCL
patients with low SUVmax appear to progress more slowly and
had better prognosis than those with high SUVmax. FDG-PET
imaging for DLBCL can be used not only for staging but also
for predicting the progression after treatment, and the SUVmax
is highly useful, since it can be measured muchmore easily and
quickly than cytological or specific pathological examinations.
Chihara et al. reported an association between high SUVmax
on FDG-PET with shorter overall survival in patients with
DLBCL [20]. Their conclusions were remarkably similar to
ours, while the SUVmax cutoff value of 30 in their study differed
greatly from that of 15 in our study. The PET/CT camera,
incorporation time, and treatment were the same between the
two studies. However, more good prognostic patients and fewer
poor prognostic patients classified by the IPI score (probably
due to patients with SUVmax values of 15–30) were included in
their report than in our study. Determination of the SUVmax
cutoff value was likely affected by individual patient character-
istics or the number of cases at the different institutes. There-
fore, a multicenter analysis may be required in order to define
the appropriate SUVmax cutoff value.
Collectively, our results suggest that the SUVmax on
FDG-PET for newly diagnosed patients with DLBCL is an
important predictor of PFS. A future prospective study to
confirm our results would be of interest.
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